The COVIDTW3 Study: Impact of Variants of Concern and Vaccination on Mortality in Intubated Patients with COVID-19-Related Respiratory Failure from 2021 to 2023

COVIDTW3 研究:2021 年至 2023 年 COVID-19 相关呼吸衰竭插管患者死亡率受关注变异株和疫苗接种的影响

阅读:1

Abstract

Background: In recent years, the severity of COVID-19 has diminished. However, some patients progressed to respiratory failure, necessitating intubation and mechanical ventilation. This study investigated the impact of variants of concern and vaccination status on mortality in mechanically ventilated patients. Method: We conducted a retrospective analysis of the medical records of intubated COVID-19 patients from 1 January 2021, to 31 December 2023. Patients who received at least one dose of a vaccine were classified as vaccinated, and variant types were classified based on the dominant variant reported by the Taiwan Centers for Disease Control. The primary outcome measured was time from intubation to all-cause in-hospital death. Result: A total of 254 patients were analyzed, comprising 65 patients infected with the Alpha variant and 189 with the Omicron variant. Clinical data, including variant type, vaccination status, and SOFA score at the time of intubation, were meticulously recorded. The overall mortality rate was 40%, with two epidemic surges occurring in 2021 and 2022. Infection with the Alpha variant was associated with a significantly higher risk of mortality (adjusted hazard ratio = 5.42 (2.78–10.7); p < 0.01). Key prognostic factors identified included age, body mass index, SOFA score, and serum bicarbonate levels. Conclusions: The overall mortality rate remained notably high. The study identified several factors associated with increased mortality risk, including older age, higher SOFA scores, Alpha variant infection, decreased serum bicarbonate levels, and lower BMI. However, vaccination status was not a significant prognostic indicator.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。